Search results
Results from the WOW.Com Content Network
Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...
In late 2011, the European Medicines Agency approved the transthyretin kinetic stabilizer Tafamidis or Vyndaqel discovered by Jeffery W. Kelly and developed by FoldRx pharmaceuticals (acquired by Pfizer in 2010) for the treatment of FAP based on clinical trial data. Tafamidis (20 mg once daily) slowed the progression of FAP over a 36-month ...
Nebivolol is a beta blocker used to treat high blood pressure and heart failure. [5] As with other β-blockers, it is generally a less preferred treatment for high blood pressure. [6] It may be used by itself or with other blood pressure medication. [6] It is taken by mouth. [6] Common side effects include dizziness, feeling tired, nausea, and ...
Each works differently, and Dr. Serwer says the most commonly prescribed blood pressure medications are: Diuretics, which lower blood pressure directly by causing the kidney to produce more urine.
Intensive blood pressure control for adults with hypertension and high cardiovascular risk can reduce the risk of mild cognitive impairment or dementia in the long term, according to a new study ...
Prior to Vyndaqel, liver transplantation was the only treatment option for FAP, and few patients could afford this expensive and difficult process. Vyndaqel has first-mover advantage and expects ...
For mild blood pressure elevation, consensus guidelines call for medically supervised lifestyle changes and observation before recommending initiation of drug therapy. However, according to the American Hypertension Association, evidence of sustained damage to the body may be present even prior to observed elevation of blood pressure.
Unfortunately for Pfizer, the list includes blockbuster drugs Eliquis, Ibrance, Vyndaqel, Xeljanz, and Xtandi. Pfizer isn't being blindsided by this patent cliff, though.